iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes

BACKGROUND. Patients with type 2 diabetes require treatment intensification to maintain glycemic control. Clinician reluctance, patient injection fears, hypoglycemia, weight gain, or other objections may lead to clinical inertia, whereby therapy is not intensified and patients live with uncontrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinnen, Debbie, Strong, Jodi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2018
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951239/
https://www.ncbi.nlm.nih.gov/pubmed/29773934
http://dx.doi.org/10.2337/ds17-0014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951239/
https://www.ncbi.nlm.nih.gov/pubmed/29773934
http://dx.doi.org/10.2337/ds17-0014

Ejemplares similares